Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloromethane SCHEMBL28762414 | 0.95 | GAA (0.41) | GAAMAPTSMN1; SMN2LMNA | |
| SCHEMBL11880108 | 0.83 | CYP2A6 (0.42) | GAAMAPTSMN1; SMN2LMNACYP3A4 | |
| SCHEMBL29441880 | 0.80 | CYP2A6 (0.39) | GAAMAPTCYP3A4 | |
| SCHEMBL6205421 | 0.80 | MAPT (0.40) | MAPTLMNAIDO1 | |
| SCHEMBL11823190 | 0.75 | NPC1 (0.46) | GAAMAPTSMN1; SMN2LMNAALOX15 | |
| SCHEMBL8903854 | 0.74 | HDAC2 (0.35) | MAPTSMN1; SMN2LMNACYP3A4 | |
| SCHEMBL30839912 | 0.74 | RAB9A (0.41) | GAAMAPTSMN1; SMN2LMNACYP3A4 | |
| SCHEMBL30120908 | 0.73 | GAA (0.34) | GAAMAPT | |
| SCHEMBL6370621 | 0.73 | GAA (0.37) | GAAMAPTSMN1; SMN2ALOX15 | |
| SCHEMBL6697803 | 0.73 | NISCH (0.43) | GAAMAPTIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | claimed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | claimed |
| CN-1964713-A | Co-use of dopamine-receptor binding compounds | DARPHARMA INC (US) | 2007-05-16 | — | — | CN | claimed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | claimed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2006012640-A3 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA INC (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| CN-1964713-A | Co-use of dopamine-receptor binding compounds | DARPHARMA INC (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| CN-1501935-A | Novel cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators | — | 2004-06-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | GAA 1590/4885MAPT 456/4885SMN1; SMN2 1094/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | GAA 1737/4885MAPT 2948/4885SMN1; SMN2 3945/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | GAA 1561/4885MAPT 453/4885SMN1; SMN2 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.